ReviewTissue engineering. Part B, Reviews2013
Amniotic fluid-derived stem cells for cardiovascular tissue engineering applications.
Review in Tissue engineering. Part B, Reviews, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 citations in OpenAlex.
- Functional hydrogels in cardiovascular therapy: Design, applications and clinical challenges (Review).International journal of molecular medicine · 2026Review
- Advances in Biomaterials for Tissue Regeneration: From Scaffold Design to CAP-Enabled Interfaces and AI-Driven Optimization.Biomimetics (Basel, Switzerland) · 2026Review
- Body Fluid-Derived Stem Cells: Powering Innovative, Less-Invasive Cell Therapies.International journal of molecular sciences · 2025Review
- Regenerative Medicine and Nanotechnology Approaches against Cardiovascular Diseases: Recent Advances and Future Prospective.Current stem cell research & therapy · 2025Review
- Exercise Improves Cardiac Dysfunction in D-Galactose-Treated Rats by Regulation of IGF-1-Humanin Pathway.Journal of aging research · 2025Article
- Serum- and xeno-free culture of human umbilical cord perivascular cells for pediatric heart valve tissue engineering.Stem cell research & therapy · 2023Article
- Increasing salinity of fibrinogen solvent generates stable fibrin hydrogels for cell delivery or tissue engineering.PloS one · 2021Article
- Conditioned Medium from Canine Amniotic Membrane-Derived Mesenchymal Stem Cells Improved Dog Sperm Post-Thaw Quality-Related Parameters.Animals : an open access journal from MDPI · 2020Article
- Cardiomyocytes Derived from HumanScientific reports · 2018Article
- Article
- Molecular basis of functional myogenic specification of Bona Fide multipotent adult cardiac stem cells.Cell cycle (Georgetown, Tex.) · 2018Review
- Differentiation of mesenchymal stem cells from human amniotic fluid to cardiomyocyte‑like cells.Molecular medicine reports · 2017Article
- Engineered Biomaterials to Enhance Stem Cell-Based Cardiac Tissue Engineering and Therapy.Macromolecular bioscience · 2016Article
- Amniotic fluid: Source of trophic factors for the developing intestine.World journal of gastrointestinal pathophysiology · 2016Review
- Modern stem cell therapy: approach to disease.Wiener klinische Wochenschrift · 2015Review
- Application of hydrogels in heart valve tissue engineering.Journal of long-term effects of medical implants · 2015Review
- The potential of mesenchymal stem cells derived from amniotic membrane and amniotic fluid for neuronal regenerative therapy.BMB reports · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Recent research has demonstrated that a population of stem cells can be isolated from amniotic fluid removed by amniocentesis that are broadly multipotent and nontumorogenic. These amniotic fluid-derived stem cells (AFSC) could potentially provide an autologous cell source for treatment of congenital defects identified during gestation, particularly cardiovascular defects. In this review, the various methods of isolating, sorting, and culturing AFSC are compared, along with techniques for inducing differentiation into cardiac myocytes and endothelial cells. Although research has not demonstrated complete and high-yield cardiac differentiation, AFSC have been shown to effectively differentiate into endothelial cells and can effectively support cardiac tissue. Additionally, several tissue engineering and regenerative therapeutic approaches for the use of these cells in heart patches, injection after myocardial infarction, heart valves, vascularized scaffolds, and blood vessels are summarized. These applications show great promise in the treatment of congenital cardiovascular defects, and further studies of isolation, culture, and differentiation of AFSC will help to develop their use for tissue engineering, regenerative medicine, and cardiovascular therapies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.